



Laboratory Technical Bulletin evolution in

Date:	Effective Date: Immediately


Title: Autoimmune Neurology Testing

Explanation of change: The paraneoplastic evaluations in serum (<u>PAVAL</u>) and spinal fluid (<u>PAC1</u>) are no longer the recommended tests for patients with suspected autoimmune neurological disorders. Instead, neurological symptom based, phenotype-specific evaluations are recommended. Each autoimmune evaluation covers the spectrum of characterized antibodies (paraneoplastic and other autoimmune) reported for that phenotype (including multifocal disorders).

Please consult the Mayo Clinic Laboratories Neurology specialty website for more information on this evolution in laboratory testing.

At maximum, one serum and one spinal fluid evaluation are required to be comprehensive.

	Symptom or Phenotype	Order ID
Brain	Encephalopathy & Epilepsy	ENS2, ENC2
	Dementia	DMS2, DMC2
	Movement Disorders	MDS2, MDC2, SPPS, SPPC
Brain & Spinal Cord	CNS Demyelinating Disease	CDS1
Spinal Cord	Myelopathy	CDS1
Autonomic	Dysautonomia	DYS2
	GI dysmotility	GID2
Peripheral Nerve	Axonal Neuropathy	AIAES
	Demyelinating Neuropathy	CIDP, MAGES
Neuromuscular	Myasthenia Gravis & Lambert- Eaton Syndrome	MGMR, MGLE
	Necrotizing Autoimmune Myopathy	NMS1
Pediatric	CNS Disorders	PCDES, PCDEC



	Date	The Section Continues Section 22 & 0
Dr. Elizabeth Plocharczyk, Laboratory Medical Director		
	Date	